Phio Pharmaceuticals Corp. (PHIO) Income Statement
PHIO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPHIO revenue and net income
PHIO profit margins
PHIO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PHIO quarterly EPS vs estimates
Phio Pharmaceuticals beat the analyst EPS estimate in 5 of the last 7 quarters. Next report: November 12, 2026 (estimate $-0.36).
PHIO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $4,362 | $21,000 | $138,000 | $15,000 | $19,000 |
| Cost of revenue | $4.6M | $3.6M | $6.3M | $193,000 | $192,000 | $3.7M | $4.3M | $4.3M | $5.4M | $5.4M |
| Gross profit | −$4.6M | −$3.6M | −$6.3M | −$193,000 | −$192,000 | −$3.7M | $21,000 | $138,000 | −$5.4M | −$5.4M |
| Research & development | $4.6M | $3.6M | $6.3M | $7.0M | $8.9M | $3.7M | $4.3M | $4.3M | $5.4M | $5.4M |
| Sales, general & admin | $4.6M | $3.7M | $4.3M | $4.5M | $4.6M | $5.1M | $4.7M | $3.2M | $4.0M | $3.6M |
| Total operating expenses | $4.6M | $3.7M | $4.5M | $11.5M | $13.5M | $5.1M | $9.0M | $7.5M | $9.4M | $9.0M |
| Operating income | −$9.2M | −$7.4M | −$10.8M | −$11.5M | −$13.5M | −$8.8M | −$9.0M | −$7.4M | −$14.1M | −$9.0M |
| Interest income | — | — | — | — | — | — | — | — | $1,000 | $15,000 |
| Interest expense | — | $231,000 | — | $175,000 | $9,000 | $0 | $0 | $0 | $1,000 | $0 |
| Income before taxes | −$8.7M | −$7.2M | −$10.8M | −$11.5M | −$13.3M | −$8.8M | −$8.9M | −$7.4M | −$14.1M | −$9.0M |
| Income taxes | — | −$7.2M | $204,000 | −$175,000 | −$75,000 | −$134,297 | −$67,000 | $4,000 | −$1.6M | −$74,000 |
| Net income | −$8.7M | −$7.2M | −$10.8M | −$11.3M | −$13.2M | −$8.8M | −$8.8M | −$7.4M | −$12.5M | −$9.0M |
| EBITDA | −$8.7M | −$7.1M | −$10.6M | −$11.3M | −$13.4M | −$8.7M | −$8.9M | −$7.3M | −$14.0M | −$9.0M |
| EPS (diluted) | −$1.45 | −$7.54 | −$15.74 | −$90.90 | −$55.40 | −$125.53 | −$2087.64 | −$4867.23 | −$25096.54 | −$46596.06 |
| Gross margin | — | — | — | — | — | −85,190.3% | 100.0% | 100.0% | −35,700.0% | −28,400.0% |
| Operating margin | — | — | — | — | — | −201,581.8% | −42,795.2% | −5,336.2% | −93,746.7% | −47,447.4% |
| Net margin | — | — | — | — | — | −201,604.8% | −42,100.0% | −5,333.3% | −83,013.3% | −47,336.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $70,000 | $0 | $0 | $30,000 | $0 | $0 |
| Cost of revenue | $1,000 | $1,000 | $1.5M | $1.2M | $1.1M | $15,000 | $985,000 | $644,000 | $866,000 | $1.1M | — | $1.8M |
| Gross profit | −$1,000 | −$1,000 | −$1.5M | −$1.2M | −$1.1M | −$15,000 | −$985,000 | −$644,000 | −$866,000 | −$1.1M | — | −$1.8M |
| Research & development | $3.1M | $2.8M | $1.5M | $1.2M | $1.1M | $886,000 | $985,000 | $644,000 | $866,000 | $1.1M | $1.0M | $1.8M |
| Sales, general & admin | $1.2M | $1.4M | $1.1M | $1.3M | $1.2M | $986,000 | $689,000 | $946,000 | $1.0M | $1.1M | $766,000 | $968,000 |
| Total operating expenses | $4.3M | $4.2M | $1.1M | $1.3M | $1.2M | $1.9M | $689,000 | $946,000 | $1.0M | $1.1M | $1.8M | $968,000 |
| Operating income | −$4.3M | −$4.2M | −$2.5M | −$2.5M | −$2.3M | −$1.9M | −$1.7M | −$1.6M | −$1.9M | −$2.2M | −$1.8M | −$2.8M |
| Interest income | $130,000 | $161,000 | — | — | $143,000 | $125,000 | — | — | — | $53,000 | — | — |
| Interest expense | — | — | — | $113,000 | — | — | — | — | — | — | — | — |
| Income before taxes | −$4.1M | −$4.0M | −$2.4M | −$2.4M | −$2.2M | −$1.8M | −$1.6M | −$1.5M | −$1.8M | −$2.2M | −$1.9M | −$2.8M |
| Income taxes | — | — | — | — | — | — | $9,276 | — | — | −$9,276 | — | −$51,000 |
| Net income | −$4.1M | −$4.0M | −$2.4M | −$2.4M | −$2.2M | −$1.8M | −$1.6M | −$1.5M | −$1.8M | −$2.2M | −$1.9M | −$2.8M |
| EBITDA | −$4.3M | −$4.0M | −$2.4M | −$2.4M | −$2.2M | −$1.8M | −$1.6M | −$1.5M | −$1.8M | −$2.1M | — | −$2.7M |
| EPS (diluted) | −$0.36 | −$0.34 | −$0.15 | −$0.44 | −$0.45 | −$0.41 | −$0.85 | −$1.54 | −$3.62 | −$1.53 | −$0.85 | −$10.26 |
| Gross margin | — | — | — | — | — | — | −1,407.1% | — | — | −3,826.7% | — | — |
| Operating margin | — | — | — | — | — | — | −2,391.4% | — | — | −7,363.3% | — | — |
| Net margin | — | — | — | — | — | — | −2,322.9% | — | — | −7,180.0% | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PHIO's financial statements (latest annual report filed March 5, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PHIO financial results
Phio Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $8.7 million. Diluted earnings per share came to −$1.45.
See the PHIO stock overview for the latest quote and news, or the PHIO chart for price history and technical indicators.
PHIO income statement FAQ
Does Phio Pharmaceuticals have revenue?
Phio Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Phio Pharmaceuticals profitable?
No. Phio Pharmaceuticals reported a net loss of $8.7 million in fiscal 2025.
How much does Phio Pharmaceuticals spend on research and development?
Phio Pharmaceuticals spent $4.6 million on research and development in fiscal 2025.
What are Phio Pharmaceuticals's earnings per share?
Phio Pharmaceuticals earned $-1.45 per diluted share in fiscal 2025, compared with $-7.54 a year earlier.
When will Phio Pharmaceuticals report its next earnings?
Phio Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Phio Pharmaceuticals's fiscal year end?
Phio Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 5, 2026.